Allogeneic CART-NKG2D cells

Phase 2Cell therapy

IInstituto de Investigación Hospital Universitario La Paz

Allogeneic CART-NKG2D cells is one of 84 biologic programs targeting Abdominal Aortic Aneurysm. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Abdominal Aortic AneurysmRecruiting

Acute Lymphoblastic LeukemiaRecruiting

Heart FailureNot yet recruiting

Abdominal Aortic AneurysmPhase 2

Recruiting

Acute Lymphoblastic LeukemiaPhase 1

Recruiting

Heart FailurePhase 2

Not yet recruiting

Competition

Competitive Landscape

206 competitors in Heart Failure

#DrugCompanyPhaseTrials

Bayer Aspirin

Bayer

Preclinical

2 2

Amidate

Pfizer

Preclinical

1 3

Allogeneic CART-NKG2D cells

IInstituto de Investigación Hospital Universitario La Paz

Phase 2

1 4

Adriamycin

Savaysa

Xifaxan

2 7

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 8

Tamiflu

CConrado Roberto Hoffmann Filho

Preclinical

1 9

Potassium Iodide

MMeda Pharmaceuticals

Preclinical

1 10

Oraverse

LLife Extension Foundation Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Not yet recruiting

Heart Failure

NCT06840275

Q4 2030

Phase 1Recruiting

Acute Lymphoblastic Leukemia

NCT06709469

Clinical

Trials by Indication[1]

Heart Failure1 trial

ASCs in Recently Diagnosed Non-ischemic Heart Failure

Not yet recruiting·CCell to Cure ApS·Phase 2·NCT06840275·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Allogeneic CART-NKG2D cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Allogeneic CART-NKG2D cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Allogeneic CART-NKG2D cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Instituto de Investigación Hospital Universitario La Paz company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: IInstituto de Investigación Hospital Universitario La Paz

Allogeneic CART-NKG2D cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2030

Trials by Indication[1]

Heart Failure1 trial

Abdominal Aortic Aneurysm1 trial

Ulcerative Colitis1 trial

Acute Lymphoblastic Leukemia1 trial

References

Drug Info

Quick Facts

Related News